Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Impact on Quality of Life (QoL) of Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Under Ibrutinib Treatment: Preliminary Data from a Real World Prospective Project (pilot study)

Maria J. Mela Osorio, MD, Carolina Pavlovsky, MD, Mariana Juni, Ms, Isolda I. Fernandez, MD, Luciana C. Ferrari, MD, Esteban Ciliberti, MD, Miguel A. Pavlovsky, MD

Blood (2017) 130 (Supplement 1): 5343.

https://doi.org/10.1182/blood.V130.Suppl_1.5343.5343

Published: 2017

Journal Articles

Results from Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with CLL

Carlos Chiattone, MD PhD, David Gomez-Almaguer, MD, Carolina Pavlovsky, MD, Elena Tuna-Aguilar, MD, Ana Lisa Basquiera, MD, Luis Palmer, MD, Danielle Leao Cordeiro De Farias, MD MSc, Sergio Schusterschitz, MD, Kenny Mauricio Galvez, Álvaro Gómez, MD, Telma Santos, MD PhD, Odin De La Mora Estrada, MD

Blood (2016) 128 (22): 5578.

https://doi.org/10.1182/blood.V128.22.5578.5578

Published: 2016

Journal Articles

"M3-M6" Molecular Response Evolution As Early Predictor of Outcome Considering Generic Vs Branded TKIs for Chronic Myeloid Leukemia (CML): An Argentine Multicentric Study

Isabel Amanda Giere, PhD M.Sc, María Jose Mela Osorio, MD, Federico Andrés Klosowski, Mariana Debus, Federico Sackmann, MD, Miguel A Pavlovsky, MD, Isolda Fernandez, MD, Elena Beatriz Moiraghi, MD, Ana Inés Varela, MD, Mariel Ana Perez, MD, Julio M. Pose Cabarcos, MD, Georgina Bendek, MD, Romina Mariano, MD, Silvina Palmer, MD, Alicia Enrico, MD, Isabel Cristina Annetta, MD, Andres L. Brodsky, MD PhD, Dante Intile, Statistic MD, Carolina Pavlovsky, MD

Blood (2016) 128 (22): 5445.

https://doi.org/10.1182/blood.V128.22.5445.5445

Published: 2016

Journal Articles

Real-World Data from Long Term Follow-up in Chronic Myeloid Leukemia (CML) Patients (PTS) Treated with Imatinib. Predictive Factors for Achievement of Deep Molecular Responses and for Failure

María Jose Mela Osorio, MD, Isabel Amanda Giere, PhD M.Sc, Isolda Fernandez, MD, Miguel A Pavlovsky, MD, Guillermina Remaggi, MD, Federico Sackmann, Dante Intile, Statistic, Carolina Pavlovsky, MD

Blood (2015) 126 (23): 5169.

https://doi.org/10.1182/blood.V126.23.5169.5169

Published: 2015

Journal Articles

Exploring the Significance of TP53, ABCB1 and GST Polymorphisms on Susceptibility and Pharmacogenetics in Argentinian Patients with Chronic Myeloid Leukemia

Natalia Weich, Master in Science, Cristian Ferri, PhD, Elena Beatriz Moiraghi, MD, Raquel Maria Nelida Bengio, MD, Isabel Amanda Giere, PhD M.Sc, Carolina Pavlovsky, MD, Irene Larripa, PhD, Ariela Freya Fundia, PhD

Blood (2015) 126 (23): 5134.

https://doi.org/10.1182/blood.V126.23.5134.5134

Published: 2015

Journal Articles

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Ana Inés Varela, MD, Romina Laura Penalba, Alicia Enrico, MD, Marta Catalan, Maria Veronica Ventriglia, Maria Josefina Freitas, Carolina Pavlovsky, MD, Susana Garbiero, PhD, Martin Beccasese, MD, Raquel Maria Nelida Bengio, MD, Catalina Abramovich, MD, Miguel A Pavlovsky, MD, Elena Beatriz Moiraghi, MD

Blood (2015) 126 (23): 5149.

https://doi.org/10.1182/blood.V126.23.5149.5149

Published: 2015

Journal Articles

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Marco Aurelio Salvino, MD PhD, Ong Tee Chuan, MD, Alaa Elhaddad, MD PhD, Kudrat Abdulkadyrov, MD PhD, Jake Shortt, MD, Hang Quach, MD, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Lee-Yung Shih, MD, Anna G. Turkina, MD PhD, Luis Meillon, MD, Yu Jin, MS, Sadhvi Khanna, MS, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 344.

https://doi.org/10.1182/blood.V126.23.344.344

Published: 2015

Journal Articles

Chronic Myeloid Leukemia (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study

Isabel Amanda Giere, PhD M.Sc, María Jose Mela Osorio, MD, Federico Andrés Klosowski, Mariana Debus, Ana Inés Varela, MD, Elena Beatriz Moiraghi, MD, Miguel A Pavlovsky, MD, Isolda Fernandez, MD, Dante Intile, Statistic, Carolina Pavlovsky, MD

Blood (2015) 126 (23): 1590.

https://doi.org/10.1182/blood.V126.23.1590.1590

Published: 2015

Journal Articles

Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience

Carolina Pavlovsky, MD, Isolda Fernandez, MD, Miguel A Pavlovsky, MD, Adriana Galeano, Federico Sackmann, Dante Intile, Statistic, Astrid Pavlovsky, MD

Blood (2015) 126 (23): 1739.

https://doi.org/10.1182/blood.V126.23.1739.1739

Published: 2015

Journal Articles

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

Timothy P. Hughes, MD, Eduardo Ciliao Munhoz, MD, Alaa Elhaddad, MD PhD, Ong Tee Chuan, MD, Kudrat Abdulkadyrov, MD, Jake Shortt, MD, Hang Quach, MD FRACP, FRCPA, MBBS, Carolina Pavlovsky, MD, Vernon J. Louw, MBChB, M.MD FCP(SA), PhDHPE), Luis Meillon, MD, Lee-Yung Shih, MD Professor, Anna G. Turkina, MD PhD, Jonathan Hwang, PharmD, MBA, Prasanna Kumar Nidamarthy, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, PhD MD

Blood (2014) 124 (21): 4542.

https://doi.org/10.1182/blood.V124.21.4542.4542

Published: 2014

Journal Articles

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Jeff H. Lipton, PhD, MD, Luis Meillon, MD, Vernon Louw, MD, Carolina Pavlovsky, MD, Lee-Yung Shih, MD, Yu Jin, Sandip Acharya, Richard C. Woodman, Timothy P. Hughes, MD, Anna G. Turkina, MD, PhD

Blood (2013) 122 (21): 4009.

https://doi.org/10.1182/blood.V122.21.4009.4009

Published: 2013

Journal Articles

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Juan Luis Steegmann, MD, PhD, Concepción Boqué, MD, Charles Chuah, MD, Carolina Pavlovsky, MD, Jiří Mayer, MD, Jon Ukropec, PhD, Mark Wildgust, PhD, Andreas Hochhaus, MD

Blood (2012) 120 (21): 1675.

https://doi.org/10.1182/blood.V120.21.1675.1675

Published: 2012

Journal Articles

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Blood (2011) 118 (21): 1701.

https://doi.org/10.1182/blood.V118.21.1701.1701

Published: 2011

Journal Articles

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

Andreas Hochhaus, MD, Giuseppe Saglio, MD, Charles Chuah, MD, Carolina Pavlovsky, MD, M. Brigid Bradley Garelick, MD, Alexandre Lambert, Neil Shah, MD, PhD

Blood (2011) 118 (21): 2767.

https://doi.org/10.1182/blood.V118.21.2767.2767

Published: 2011

Journal Articles

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Carolina Pavlovsky, MD, Santiago Pavlovsky, MD PhD, Maria L. Pardo, MD, Sandra Sapia, MD, Mariela Monreal, MD, Claudia Corrado, MDd, Miguel A. Pavlovsky, MD, Isolda Fernandez, MD, Mariana Juni, MS

Blood (2006) 108 (11): 4968.

https://doi.org/10.1182/blood.V108.11.4968.4968

Published: 2006

Journal Articles

Combined Chemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Santiago Pavlovsky, MD, PhD, Carolina Pavlovsky, MD, Laura Pardo, MD, Sandra Sapia, MD, Isolda I. Fernandez, MD, Mariana Juni

Blood (2005) 106 (11): 5033.

https://doi.org/10.1182/blood.V106.11.5033.5033

Published: 2005

Journal Articles

CD38 Expression Has an Important Value among Prognostic Factors in Chronic Lymphocytic Leukemia (CLL): A Multivariate Analysis in 160 Patients.

Carolina Pavlovsky, MD, Miguel A. Pavlovsky, MD, Maria L. Pardo, MD, Sandra Sapia, MD, Pablo Mountford, MD, Isolda I. Fernandez, MD, Claudia S. Corrado, MD, Mariana Juni Statistics, Santiago Pavlovsky, MD PhD

Blood (2004) 104 (11): 4779.

https://doi.org/10.1182/blood.V104.11.4779.4779

Published: 2004

NARROW

Impact on Quality of Life (QoL) of Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Under Ibrutinib Treatment: Preliminary Data from a Real World Prospective Project (pilot study)

Results from Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with CLL

"M3-M6" Molecular Response Evolution As Early Predictor of Outcome Considering Generic Vs Branded TKIs for Chronic Myeloid Leukemia (CML): An Argentine Multicentric Study

Real-World Data from Long Term Follow-up in Chronic Myeloid Leukemia (CML) Patients (PTS) Treated with Imatinib. Predictive Factors for Achievement of Deep Molecular Responses and for Failure

Exploring the Significance of TP53, ABCB1 and GST Polymorphisms on Susceptibility and Pharmacogenetics in Argentinian Patients with Chronic Myeloid Leukemia

Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina

Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study

Chronic Myeloid Leukemia (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study

Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience

Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis

ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Combined Chemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

CD38 Expression Has an Important Value among Prognostic Factors in Chronic Lymphocytic Leukemia (CLL): A Multivariate Analysis in 160 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only